Previous close | 388.00 |
Open | 385.00 |
Bid | 391.50 x 0 |
Ask | 392.00 x 0 |
Day's range | 381.00 - 393.50 |
52-week range | 227.50 - 393.50 |
Volume | |
Avg. volume | 16,308 |
Market cap | 5.351B |
Beta (5Y monthly) | 1.00 |
PE ratio (TTM) | 73.41 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 1.30 (0.38%) |
Ex-dividend date | 03 July 2023 |
1y target est | N/A |
WALTHAM, Mass., October 26, 2023--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, and Ypsomed AG (SIX: YPSN), the leading developer and manufacturer of injection and infusion systems for self-medication have signed a supply agreement for Ypsomed’s customizable YpsoMate 2.25 autoinjector pen device with a fill volume of 2.0 milliliters.